Related Experiment Videos
Immediate hypersensitivity to mannitol: a potential cause of apparent hypersensitivity to cisplatin
Cancer Treatment Reports
|May 1, 1985
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM study.
Annals of oncology : official journal of the European Society for Medical Oncology·2016
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Annals of oncology : official journal of the European Society for Medical Oncology·2011
Association of thymidylate synthase enhancer region polymorphisms with thymidylate synthase activity in vivo.
The pharmacogenomics journal·2010
Cisplatin as a first-line treatment in T2 and T3 bladder carcinoma.
Cancer treatment reports·1987
IV melphalan in children.
Cancer treatment reports·1987
Interactions of methotrexate and cyclophosphamide with the pharmacokinetics of 5-fluorouracil in an animal model.
Cancer treatment reports·1987
Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.
Cancer treatment reports·1987
Doxorubicin distribution in human breast cancer.
Cancer treatment reports·1987
Phase I study of echinomycin.
Cancer treatment reports·1987
Therapeutic JAK Inhibition in Idiopathic Subglottic Stenosis.
The Laryngoscope·2026
Potent IgE-Mediated Allergenic Reduction in Human Serum by Casein-Polyphenol Conjugates Makes Personalized Oral Immunotherapy Credible.
ACS food science & technology·2026